Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine.
作者信息
Shimabukuro Tom, Nair Narayan
机构信息
Immunization Safety Office, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Division of Epidemiology, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland.
出版信息
JAMA. 2021 Feb 23;325(8):780-781. doi: 10.1001/jama.2021.0600.
Abstract
摘要
相似文献
1
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine.接种辉瑞-生物科技公司新冠疫苗第一剂后包括过敏反应在内的过敏反应。
JAMA. 2021 Feb 23;325(8):780-781. doi: 10.1001/jama.2021.0600.
2
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020.美国 2020 年 12 月 14 日至 23 日：在接种第一剂辉瑞-BioNTech COVID-19 疫苗后出现过敏反应（包括过敏反应）。
MMWR Morb Mortal Wkly Rep. 2021 Jan 15;70(2):46-51. doi: 10.15585/mmwr.mm7002e1.
3
Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine - United States, December 14-23, 2020.2020年12月14日至23日美国接种首剂辉瑞-生物科技公司新冠病毒疫苗后发生的过敏反应，包括过敏反应。
Am J Transplant. 2021 Mar;21(3):1332-1337. doi: 10.1111/ajt.16516.
4
Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk.高过敏风险成年人接种辉瑞-BioNTech COVID-19 疫苗后的过敏反应发生率。
JAMA Netw Open. 2021 Aug 2;4(8):e2122255. doi: 10.1001/jamanetworkopen.2021.22255.
5
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021.美国 2020 年 12 月 21 日-2021 年 1 月 10 日期间，在接种 Moderna COVID-19 疫苗第一针后出现过敏反应（包括过敏反应）。
MMWR Morb Mortal Wkly Rep. 2021 Jan 29;70(4):125-129. doi: 10.15585/mmwr.mm7004e1.
6
Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine - United States, December 21, 2020-January 10, 2021.2020年12月21日至2021年1月10日美国接种第一剂莫德纳新冠疫苗后的过敏反应，包括过敏反应
Am J Transplant. 2021 Mar;21(3):1326-1331. doi: 10.1111/ajt.16517.
7
COVID-19 vaccine-related presumed allergic reactions and second dose administration by using a two-step graded protocol.使用两步分级方案管理与 COVID-19 疫苗相关的疑似过敏反应和第二剂接种。
Allergy Asthma Proc. 2021 Nov 1;42(6):515-521. doi: 10.2500/aap.2021.42.210075.
8
Acute Allergic Reactions to mRNA COVID-19 Vaccines.mRNA COVID-19 疫苗的急性过敏反应。
JAMA. 2021 Apr 20;325(15):1562-1565. doi: 10.1001/jama.2021.3976.
9
Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021.2020年12月14日至2021年1月18日美国接种mRNA新冠疫苗后发生过敏反应的报告
JAMA. 2021 Mar 16;325(11):1101-1102. doi: 10.1001/jama.2021.1967.
10
[Allergy to Pfizer-BioNTech® vaccine demonstrated by skin testing].[通过皮肤试验证明对辉瑞 - 生物科技公司疫苗过敏]
Rev Alerg Mex. 2023 Jan 4;69(2):89-92. doi: 10.29262/ram.v69i2.1088.
引用本文的文献
1
Impact of COVID-19 vaccination on cancer patients: safety, efficacy, and long-term effects.2019冠状病毒病疫苗接种对癌症患者的影响：安全性、有效性及长期影响
Support Care Cancer. 2025 Aug 4;33(8):753. doi: 10.1007/s00520-025-09783-1.
2
Nanotechnology-based mRNA vaccines.基于纳米技术的mRNA疫苗。
Nat Rev Methods Primers. 2023;3(1). doi: 10.1038/s43586-023-00246-7. Epub 2023 Aug 17.
3
Beyond the Pandemic Era: Recent Advances and Efficacy of SARS-CoV-2 Vaccines Against Emerging Variants of Concern.后疫情时代：SARS-CoV-2疫苗针对新出现的关注变异株的最新进展与效果
Vaccines (Basel). 2025 Apr 17;13(4):424. doi: 10.3390/vaccines13040424.
4
Adverse reactions to mRNA COVID-19 vaccine in people with allergies in Japan.日本过敏人群对新冠mRNA疫苗的不良反应。
Glob Health Med. 2024 Dec 31;6(6):363-374. doi: 10.35772/ghm.2024.01053.
5
Polyethylene Glycols Stimulate Ca Signaling, Cytokine Production, and the Formation of Neutrophil Extracellular Traps.聚乙二醇刺激钙信号传导、细胞因子产生及中性粒细胞胞外陷阱的形成。
Int J Nanomedicine. 2024 Dec 7;19:13165-13181. doi: 10.2147/IJN.S479710. eCollection 2024.
6
Regulation of protein thermal stability and its potential application in the development of thermo-attenuated vaccines.蛋白质热稳定性的调控及其在热减毒疫苗开发中的潜在应用。
Eng Microbiol. 2024 Jun 25;4(3):100162. doi: 10.1016/j.engmic.2024.100162. eCollection 2024 Sep.
7
How a Novel Approach of Allergy Call Center Improved the Management of the Anti-COVID Vaccination Campaign in Piedmont: Italy.一种新型过敏呼叫中心方法如何改善意大利皮埃蒙特地区抗新冠疫苗接种运动的管理
J Epidemiol Glob Health. 2024 Dec;14(4):1764-1770. doi: 10.1007/s44197-024-00309-2. Epub 2024 Oct 14.
8
Safety of COVID-19 Vaccines among People with History of Allergy: A European Active Surveillance Study.有过敏史人群中新冠疫苗的安全性：一项欧洲主动监测研究
Vaccines (Basel). 2024 Sep 17;12(9):1059. doi: 10.3390/vaccines12091059.
9
COVID-19 vaccines: anaphylaxis and anxiety : A case study from an allergy unit.COVID-19 疫苗：过敏反应和焦虑：过敏科的一个病例研究。
Wien Klin Wochenschr. 2024 Nov;136(21-22):590-597. doi: 10.1007/s00508-024-02435-0. Epub 2024 Sep 11.
10
Generalized Eruptive Keratoacanthoma (GEKA) after Pfizer mRNABNT162b2 (Comirnaty) COVID-19 Vaccination Successfully Treated with Cemiplimab.辉瑞 mRNA（BNT162b2，Comirnaty）COVID-19 疫苗接种后发生泛发性发疹性角化棘皮瘤（GEKA），成功用西普利单抗治疗。
Viruses. 2024 Aug 6;16(8):1260. doi: 10.3390/v16081260.
本文引用的文献
1
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020.美国 2020 年 12 月 14 日至 23 日：在接种第一剂辉瑞-BioNTech COVID-19 疫苗后出现过敏反应（包括过敏反应）。
MMWR Morb Mortal Wkly Rep. 2021 Jan 15;70(2):46-51. doi: 10.15585/mmwr.mm7002e1.
2
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020.免疫实践咨询委员会关于使用辉瑞-BioNTech COVID-19 疫苗的临时建议-美国，2020 年 12 月。
MMWR Morb Mortal Wkly Rep. 2020 Dec 18;69(50):1922-1924. doi: 10.15585/mmwr.mm6950e2.
3
Excess Deaths Associated with COVID-19, by Age and Race and Ethnicity - United States, January 26-October 3, 2020.与 COVID-19 相关的超额死亡人数，按年龄、种族和族裔划分 - 美国，2020 年 1 月 26 日至 10 月 3 日。
MMWR Morb Mortal Wkly Rep. 2020 Oct 23;69(42):1522-1527. doi: 10.15585/mmwr.mm6942e2.
4
Vaccine-associated hypersensitivity.疫苗相关过敏反应。
J Allergy Clin Immunol. 2018 Feb;141(2):463-472. doi: 10.1016/j.jaci.2017.12.971.
5
Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).疫苗不良事件报告系统（VAERS）中的安全性监测。
Vaccine. 2015 Aug 26;33(36):4398-405. doi: 10.1016/j.vaccine.2015.07.035. Epub 2015 Jul 22.
6
Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data.过敏反应：免疫接种安全性数据的病例定义及数据收集、分析与呈现指南
Vaccine. 2007 Aug 1;25(31):5675-84. doi: 10.1016/j.vaccine.2007.02.064. Epub 2007 Mar 12.
Zotero 插件